At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
ICON-1biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Who Are Planned to Undergo Enucleation or Brachytherapy
In Brief
A Phase 1 clinical trial evaluating ICON-1 for Uveal Melanoma and Choroid Neoplasm. Completed, enrolled 10 participants across 8 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveal Melanoma, Choroid Neoplasm
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedMay 2016
Primary CompletionSep 2017
TodayJul 2026
First PostedMay 13, 2016
Enrollment StartMay 1, 2016
Primary CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.1 years ago
Interventions
ICON-1biological
Intravitreal injection of ICON-1